# Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone

> **NCT00396357** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 914 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Vildagliptin
- **DRUG:** metformin

## Key facts

- **NCT ID:** NCT00396357
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-06
- **Final completion:** —
- **Target enrollment:** 914 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396357, "Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00396357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*